InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 2 February 2024

MaxiNovel: This phase I trial is testing a new oral drug in patients with advanced cancers (excluding some types of blood cancer)A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor

Clinical summary

Summary

This is a dose escalation and expansion study, in which eligible patients will receive oral MAX-10181 once or twice a day, with dose modifications based on set tolerability criteria. In part two of the study, eligible participants will receive oral MAX-10181 at a recommended dose, based on the outcomes of study part one.

Conditions

This trial is treating patients with advanced solid cancers (excluding some types of blood cancer).

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I

Trial Acronym

MaxiNovel

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Maxinovel Pty., Ltd.

Scientific Title

A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor

Eligibility

Inclusion

  • Males and/or females over age 18.
  • Histologically or cytologically confirmed advanced or metastatic solid tumor for which no established standard therapy is available.
  • At least one measurable lesion by CT or MRI according to RECIST1.1, which is not in irradiated area (only for expansion phase).
  • Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (in case of alopecia, Grade 2 is acceptable).
  • Life expectancy of at least 3 months.
  • Female participants of child bearing potential agree not to be pregnant or lactating during the study and for three months following the last dose of study drug. Both men and women of reproductive potential must agree to use a highly effective method of birth control during the study and for three months following the last dose of study drug. A highly effective method of contraception is defined as one that results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly.

Exclusion

  • Laboratory values not within the Protocol-defined range.
  • Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
  • Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery.
  • Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  • Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), hormone therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
  • Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis.
  • History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation.
  • Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.

Inclusion

  • You are able to swallow medication by mouth.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.